Skip Navigation

Low dose rate brachytherapy for localised prostate cancer

Guidance issued Guidance issued
 
IP Guidance Number: IPG132
 
Summary:

The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on low dose rate brachytherapy for localised prostate cancer.
Description:
 Prostate cancer is one of the most common cancers in men. It tends to affect older men, with the risk rising with age. It is not a single disease entity but may be indicated form an incidental biopsy finding to presentation with metastatic prostate cancer, which may or may not cause any symptoms or shorten life. Symptoms when they occur include urinary outflow obstruction and features of metastases, such as bone pain. Prognosis with prostate cancer is variable and depends on the grade of the tumour and stage of the diagnosed cancer. Treatment options depend on the stage of the cancer. Current treatments for localised prostate cancer include watchful waiting, radiotherapy, and radical prostatectomy. Metastatic prostate cancer is usually treated with hormone therapy. Brachytherapy is a form of radiotherapy in which delivery of radiation is targeted directly to the prostate gland through the implantation of small radioactive pellets. Needles are inserted through the skin of the perineum, these needles deliver the seeds which can be left either permanently or temporarily (high dose). These seeds give off radiation at a low dose over several weeks or months, remaining in the prostate gland permanently. In high dose rate brachytherapy thin plastic catheters are inserted through a template, through the perineal skin, and into the prostate gland. They enter the skin below the scrotum and above the rectum. A radioactive seeds are then inserted into each catheter. The catheters are then pulled out, leaving no radioactive material in the prostate gland. Brachytherapy may be used as a primary therapy (monotherapy), in combination with external beam radiation (EBRT) in high dose therapy.
Arrangements:

Other (see guidance)
Topic Area:

Cancer
Therapeutic procedures
Urogenital
Specialty:

Clinical oncology
Medical oncology
Specialist advice has
been sought from:
Date notified to NICE: 01 April 2002
Provisional Consultation Date: April 2005
Guidance Publication Date: 27 July 2005
Contact Details:
Project Manager
(for general enquiries or comments)		 Ben Doak
ip@nice.org.uk
Technical Lead
(for procedure specific enquiries or comments) 		Sally Wortley
ip@nice.org.uk
Contact Address:

Interventional Procedures Programme
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA
Links:

Search NICE guidance


Advanced guidance search

Related information

See NICE guidance in practice

Related guidance

Click the links below to see guidance on similar topics

Order NICE guidance

Order printed copies of our guidance